Neuro-SysMed — a centre for clinical treatment research on neurological diseases

A Norwegian–Swedish study, now published in the New England Journal of Medicine, shows that the low-cost drug rituximab is as effective as ocrelizumab, one of the most effective treatments available for multiple sclerosis (MS). At the same time, the use of rituximab saves the Norwegian healthcare system approximately NOK 500 million every year.

The OVERLORD MS study, led by the MS research group at Neuro SysMed, Haukeland University Hospital and the University of Bergen, has been awarded “Investigator Initiated Study of the Year” at the national Award for Outstanding Contribution to Clinical Studies 2025. The prize was presented at the Grand Hotel in Oslo on 29 January, 2026.

On Wednesday, November 19, 2025, Neuro-SysMed concluded its Annual Symposium 2025 after two inspiring days filled with cutting-edge science, collaboration, networking, and lively discussions. With over 150 dedicated participants, the event showcased the latest advances in neurological research and set the stage for future breakthroughs.

The RSTN was established in March 2021 and offers education for PhD candidates and others, with the aim to provide students with insights into groundbreaking translational neuroscience.